FDA MedWatch—Updates to Medical Device Shortage List: Disruptions in Availability of Hemodialysis Bloodlines – Letter to Health Care Providers

The U.S. Food and Drug Administration (FDA) is aware that the U.S. is experiencing interruptions in the supply of hemodialysis bloodlines because of recent supplier issues. The disruption in supply of this device is expected to impact patient care and as such may require adjustments to the clinical management of patients receiving acute or chronic hemodialysis. The FDA expects the duration of this shortage to extend through early fall of 2025. The FDA recommends health care providers consider strategies to conserve the use of hemodialysis bloodlines when possible.

On January 8, 2025, B. Braun issued a customer letter detailing an interruption in the production and supply of certain hemodialysis bloodlines as well as available market alternatives for these products.

Recommendations

The FDA recommends health care providers experiencing interruptions or shortages in supply of hemodialysis bloodlines develop strategies to conserve their use. Providers should use their clinical judgment when developing and implementing conservation strategies.

In developing strategies to preserve the supply for patients at highest risk, please consider the following:

• Continue to provide dialysis treatments to your patients.
• Monitor current and future supplies of bloodlines.
• Develop plans and implement strategies to conserve the supply of bloodlines and reduce the impact on patient care.
• Be aware the FDA is working with manufacturers to understand the availability of devices and develop mitigation strategies, if needed.
• Remain alert for further updates and recommendations from the FDA and applicable manufacturers.
• Refer to the following guidelines for best practices for the care of patients receiving hemodialysis:

• • Kidney Disease Outcomes Quality Initiative (KDOQI) Update of the KDOQI Clinical Practice Guideline for Hemodialysis Adequacy.

Voluntarily report any concerns with supply chain and/or shortages of hemodialysis bloodlines to the FDA at [email protected].

The FDA will keep health care providers and the public informed as new or additional information becomes available.